Bortezomib, Paclitaxel, and Carboplatin as a First-Line Regimen for Patients with Metastatic Esophageal, Gastric, and Gastroesophageal Cancer: Phase II Results from the North Central Cancer Treatment Group (N044B)
Authors:
- 1 May 2008
- journal article
- research article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 3 (5) , 516-520
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Incorporating Bortezomib into the Treatment of Lung CancerClinical Cancer Research, 2007
- Antitumor effects and drug interactions of the proteasome inhibitor bortezomib (PS341) in gastric cancer cellsAnti-Cancer Drugs, 2007
- Novel targets in gastric and esophageal cancerCritical Reviews in Oncology/Hematology, 2006
- A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade™), in combination with paclitaxel and carboplatin in patients with advanced malignanciesCancer Chemotherapy and Pharmacology, 2006
- Bortezomib for Myeloma — Much Ado about SomethingNew England Journal of Medicine, 2005
- Bortezomib or High-Dose Dexamethasone for Relapsed Multiple MyelomaNew England Journal of Medicine, 2005
- A phase II study of carboplatin and paclitaxel in esophageal cancerAnnals of Oncology, 2004
- The proteasome: a suitable antineoplastic targetNature Reviews Cancer, 2004
- Preoperative chemotherapy for esophageal cancer with paclitaxel and carboplatin: results of a phase II trialThe Journal of Thoracic and Cardiovascular Surgery, 2003
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000